Opioid Use and Its Relationship to Cardiovascular Disease and Brain Health: A Presidential Advisory From the American Heart Association

The misuse of opioids continues to be epidemic, resulting in dependency and a recent upsurge in drug overdoses that have contributed to a significant decrease in life expectancy in the United States. Moreover, recent data suggest that commonly used opioids for the management of pain may produce undesirable pharmacological actions and interfere with critical medications commonly used in cardiovascular disease and stroke; however, the impact on outcomes remains controversial. The American Heart Association developed an advisory statement for health care professionals and researchers in the setting of cardiovascular and brain health to synthesize the current literature, to provide approaches for identifying patients with opioid use disorder, and to address pain management and overdose. A literature and internet search spanning from January 1, 2012, to February 15, 2021, and limited to epidemiology studies, reviews, consensus statements, and guidelines in human subjects was conducted. Suggestions and considerations listed in this document are based primarily on published evidence from this review whenever possible, as well as expert opinion. Several federal and institutional consensus documents and clinical resources are currently available to both patients and clinicians; however, none have specifically addressed cardiovascular disease and brain health. Although strategic tools and therapeutic approaches for recognition of opioid use disorder and safe opioid use are available for health care professionals who manage patients with cardiovascular disease and stroke, high-quality evidence does not currently exist. Therefore, there is an urgent need for more research to identify the most effective approaches to improve care for these patients.

[1]  M. Kariisa,et al.  Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013–2019 , 2021, MMWR. Morbidity and mortality weekly report.

[2]  The Occupational Health Nurse's (OHNs) Role in Addressing the Opioid Crisis in the Workplace. , 2020, Workplace health & safety.

[3]  P. Kudenchuk,et al.  Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. , 2020, Circulation.

[4]  Wenzhi Sun,et al.  Brain control of humoral immune responses amenable to behavioural modulation , 2020, Nature.

[5]  B. Madras,et al.  Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System. , 2020, NAM perspectives.

[6]  J. Trafton,et al.  Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation , 2020, BMJ.

[7]  David K. Wyant,et al.  Compositional and contextual factors associated with drug overdose deaths in the United States , 2020, Journal of addictive diseases.

[8]  Jennifer G. Lyons,et al.  Incidence of Opioid Overdose Among Patients Using ER/LA Opioid Analgesics Before and After Implementation of the Class-Wide Opioid Risk Evaluation and Mitigation Strategy , 2020, Journal of pain research.

[9]  Holly Hedegaard,et al.  Drug Overdose Deaths in the United States, 1999-2018. , 2020, NCHS data brief.

[10]  E. Stuart,et al.  Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review. , 2019, JAMA internal medicine.

[11]  J. Blankenship,et al.  Barriers to use of radial access for percutaneous coronary intervention , 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[12]  W. Compton,et al.  Patient-Centered Reduction or Discontinuation of Long-term Opioid Analgesics: The HHS Guide for Clinicians. , 2019, JAMA.

[13]  Christopher M. Jones,et al.  Epidemiology of the U.S. opioid crisis: the importance of the vector , 2019, Annals of the New York Academy of Sciences.

[14]  H. Kamel,et al.  Response by Salehi Omran and Kamel to Letter Regarding Article, "National Trends in Hospitalizations for Stroke Associated With Infective Endocarditis and Opioid Use Between 1993 and 2015". , 2019, Stroke.

[15]  R. Dart,et al.  Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy , 2019, Pain medicine.

[16]  H. Kamel,et al.  National Trends in Hospitalizations for Stroke Associated With Infective Endocarditis and Opioid Use Between 1993 and 2015 , 2019, Stroke.

[17]  J. Trecki A Perspective Regarding the Current State of the Opioid Epidemic. , 2019, JAMA network open.

[18]  Holly Hedegaard,et al.  Drug Overdose Deaths in the United States, 1999-2017. , 2018, NCHS data brief.

[19]  M. Makary,et al.  Opioid-Prescribing Guidelines for Common Surgical Procedures: An Expert Panel Consensus. , 2018, Journal of the American College of Surgeons.

[20]  N. Volkow,et al.  Helping to End Addiction Over the Long-term: The Research Plan for the NIH HEAL Initiative. , 2018, JAMA.

[21]  W. Schaffner,et al.  Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs — Six Sites, 2005–2016 , 2018, MMWR. Morbidity and mortality weekly report.

[22]  D. Seelig,et al.  Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose , 2018, Scientific Reports.

[23]  N. Mewton,et al.  Effect and Safety of Morphine Use in Acute Anterior ST‐Segment Elevation Myocardial Infarction , 2018, Journal of the American Heart Association.

[24]  Nabarun Dasgupta,et al.  Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. , 2018, American journal of public health.

[25]  J. Bobes,et al.  Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus , 2017, Expert opinion on pharmacotherapy.

[26]  Christopher M. Jones,et al.  Promising roles for pharmacists in addressing the U.S. opioid crisis. , 2017, Research in social & administrative pharmacy : RSAP.

[27]  F I Carroll,et al.  Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse , 2017, PloS one.

[28]  Likang Xu,et al.  Annual surveillance report of drug-related risks and outcomes -- United States, 2017 , 2017 .

[29]  R. Bonnie,et al.  Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use , 2017 .

[30]  A. Fleischauer,et al.  Hospitalizations for Endocarditis and Associated Health Care Costs Among Persons with Diagnosed Drug Dependence — North Carolina, 2010–2015 , 2017, MMWR. Morbidity and mortality weekly report.

[31]  W. Gellad,et al.  Addressing the Opioid Epidemic in the United States: Lessons From the Department of Veterans Affairs. , 2017, JAMA internal medicine.

[32]  Naihua Duan,et al.  An Overview of Research and Evaluation Designs for Dissemination and Implementation. , 2017, Annual review of public health.

[33]  T. Grosser Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 2017, The New England journal of medicine.

[34]  F. Gomez-Pinilla,et al.  Specific behavioral and cellular adaptations induced by chronic morphine are reduced by dietary omega-3 polyunsaturated fatty acids , 2017, PloS one.

[35]  D. Baker History of The Joint Commission's Pain Standards: Lessons for Today's Prescription Opioid Epidemic. , 2017, JAMA.

[36]  P. Libby,et al.  Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 2016, The New England journal of medicine.

[37]  I. Xanthopoulou,et al.  Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. , 2016, International journal of cardiology.

[38]  J. Lekakis,et al.  P2Y12 Receptor Antagonists and Morphine: A Dangerous Liaison? , 2016, Circulation. Cardiovascular interventions.

[39]  Harold Alan Pincus,et al.  Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians. , 2016, Health affairs.

[40]  N. Danchin,et al.  Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. , 2016, European heart journal.

[41]  Roger Chou,et al.  Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. , 2016, The journal of pain : official journal of the American Pain Society.

[42]  E. Sinz,et al.  Part 14: Education: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. , 2015, Circulation.

[43]  A. Bolger,et al.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association , 2015, Circulation.

[44]  J. Gudin,et al.  Opioid Related Endocrinopathy. , 2015, Pain medicine.

[45]  George Davey-Smith,et al.  Social Determinants of Risk and Outcomes for Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2015, Circulation.

[46]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[47]  H. Surratt,et al.  The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. , 2014, JAMA psychiatry.

[48]  M. Posch,et al.  Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. , 2014, Journal of the American College of Cardiology.

[49]  G. Pasternak,et al.  Mu Opioids and Their Receptors: Evolution of a Concept , 2013, Pharmacological Reviews.

[50]  P. Conaghan A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity , 2011, Rheumatology International.

[51]  Ilana B. Witten,et al.  Cholinergic Interneurons Control Local Circuit Activity and Cocaine Conditioning , 2010, Science.

[52]  A. Zee The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy , 2009 .

[53]  Art Van Zee,et al.  The Promotion and Marketing of OxyContin : Commercial Triumph , Public Health Tragedy , 2009 .

[54]  Jill Manit,et al.  National Survey on Drug Use and Health , 2009 .

[55]  Howard S. Smith,et al.  Opioid metabolism. , 2009, Mayo Clinic proceedings.

[56]  W. Gibler,et al.  Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. , 2005, American heart journal.

[57]  Accreditation Council for Graduate Medical Education Mourns Marvin R. Dunn, Director of Residency Review Committee Activities , 2003, Journal of Investigative Medicine.

[58]  S. Galea,et al.  Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. , 2002, Public health reports.

[59]  H. Jick,et al.  Addiction rare in patients treated with narcotics. , 1980, The New England journal of medicine.

[60]  K. Jenpanich,et al.  [Drug administration]. , 1976, Thai journal of nursing.

[61]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.